Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tart Cherry Juice for the Prevention of Paclitaxel-Induced Neuropathy
NCT06268665Phase 2Recruiting
- Sponsor
- University of California, Davis
- Start
- Aug 2024
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in peripheral neuropathy (2 arms), sponsored by University of California, Davis. Primary endpoint: Efficacy of tart cherry juice supplementation in the prevention of paclitaxel-induced peripheral neuropathy (PIPN) at 1 year. Started Aug 2024; status: recruiting.
02
Conditions
peripheral neuropathy
Beyond the preview
Go deeper on NCT06268665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268665.